| 林劲冠 石朝晖 崔自重 余智渊 何喆.培美曲塞与吉西他滨联合卡铂治疗初治老年晚期肺腺癌的临床观察[J].现代生物医学进展英文版,2014,14(27):5257-5259. |
| 培美曲塞与吉西他滨联合卡铂治疗初治老年晚期肺腺癌的临床观察 |
| Efficacy of Pemetrexed or Gemcitabine Combined with Carboplatin in theTreatment of Elderly Patients with Advanced Lung Adenocarcinoma |
| |
| DOI： |
| 中文关键词: 肺腺癌 培美曲塞 吉西他滨 卡铂 |
| 英文关键词: Lung adenocarcinoma Pemetrexed Gemcitabine Carboplatin |
| 基金项目:湖南省卫生厅科研计划资助项目(B2013-101) |
|
| Hits: 839 |
| Download times: 1044 |
| 中文摘要: |
| 目的：比较培美曲塞与吉西他滨联合卡铂治疗初治老年晚期肺腺癌的疗效和安全性。方法：收集2010 年1 月-2011 年12 月
我院≥ 65 岁的Ⅲb 期和Ⅳ期肺腺患者84 例，随机分为培美曲塞联合卡铂(PC)组：培美曲塞500 mg／m2d1，卡铂按曲线下面积
(Auc)=5 的剂量水平d2；吉西他滨联合卡铂(GC)组：吉西他滨1000 mg／m2 d1,8，卡铂按Auc=5 的剂量水平d2，两组1 个治疗周
期均为21 d，每组42 例，比较两组患者的有效率，不良反应及1、2 年生存率。结果：PC 组和GC组总有效率分别为28.6％和19％
(P<0.05)，疾病控制率分别为73.8%和57.1%(P<0.05)；两组的中位PFS 分别为11.8 个月和10.2 个月(P>0.05)，1 年生存率分别为
52.3%和51.2％(P>0.05)，2 年生存率分别为24.1％和22.4％(P>0.05)；PC组患者白细胞减少、贫血及血小板减少的不良反应发生
率均明显低于GC组(P<0.05)。结论：培美曲塞联合卡铂与吉西他滨联合卡铂对初治老年晚期肺腺癌的疗效相近，但前者可能更
安全；PC方案可作为老年晚期肺腺癌有效的一线化疗方案。 |
| 英文摘要: |
| Objective:To compare the efficacy and safety of pemetrexed or gemcitabine combined with carboplatin in the
treatment of elderly patients with advanced lung adenocarcinoma.Methods:From January 2010 to December 2011 in our hospital, 84
elderly patients (≥ 65) with stage Ⅲ b and Ⅳ lung adenocarcinoma were collected, and randomly divided into pemetrexed plus
carboplatin group(PC) with 42 cases and gemcitabine plus carboplatin group(GC) with 42 cases. PC group was received pemetrexed 500
mg /m2 d1 and carboplatin in the area under the curve (Auc) of =5 d2, whereas GC group was recieved gemcitabine 1000 mg/m2 d1,8,
and carboplatin at a dose of Auc=5 level d2. One treatment cycles were 21 days. The efficiency, adverse reactions and 1, 2 year survival
rate were compared.Results:The total effective rates in PC group and GC group were 28.6%and 19%(P<0.05) respectively. The disease
control rates were 73.8%and 57.1%(P<0.05). The median PFS were 11.8 and 10.2 months(P>0.05).1 year survival rates were 52.3%and
51.2% (P>0.05). 2 years survival rates were 24.1% and 22.4% (P>0.05). In the PC group,?leukopenia, anemia and thrombocytopenia
were significantly lower than those in the GC group (P<0.05).Conclusion:The efficacy of pemetrexed or gemcitabine combined with
carboplatin in the treatment of elderly patients with advanced lung adenocarcinoma was roughly similar, but the former may be less
adverse reactions. Therefore pemetrexed combined with carboplatin can be used as a safe and effective drug for clinical first-line
treatment for the elderly patients with advanced lung adenocarcinoma. |
|
View Full Text
View/Add Comment Download reader |
| Close |
